uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
uniQure N.V. - Ordinary Shares (QURE)
Last uniqure n.v. - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
uniqure.com/investors-newsroom/overview.php
Company Research
Source: GlobeNewswire
~ Increases in FIX Activity Sustained at up to 57% of Normal, with Mean FIX of 47% of Normal at Six Months After Administration ~ ~ None of the Patients Received Factor Infusions or Reported Bleeding Events Over a Combined 78 Weeks of Observation ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 10, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced updated clinical data in patients treated in the Company’s ongoing Phase IIb study of AMT-061, an investigational AAV5-based gene therapy containing a patent-protected FIX-Padua variant, for the treatment of patients with severe and moderately severe hemophilia B. These data are being presented today at the Hemostasis & Thrombosis Research Society (HTRS) 2019 Scientific Symposium and show that clinically significant elevations of Factor IX (FIX) activity continue to be sustained in all three patien
Show less
Read more
Impact Snapshot
Event Time:
QURE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QURE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QURE alerts
High impacting uniQure N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
QURE
News
- uniQure (NASDAQ: QURE) had its price target raised by analysts at Mizuho from $7.00 to $20.00. They now have a "neutral" rating on the stock.MarketBeat
- uniQure (NASDAQ: QURE) had its price target raised by analysts at Stifel Nicolaus from $12.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
- Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025? [Yahoo! Finance]Yahoo! Finance
- uniQure (NASDAQ: QURE) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $9.00 to $20.00. They now have a "neutral" rating on the stock.MarketBeat
- uniQure (NASDAQ: QURE) was upgraded by analysts at Wells Fargo & Company from a "hold" rating to a "strong-buy" rating.MarketBeat
QURE
Earnings
- 11/5/24 - Beat
QURE
Sec Filings
- 12/17/24 - Form SCHEDULE
- 12/12/24 - Form 4
- 12/10/24 - Form 4
- QURE's page on the SEC website